Evaluation of Fidaxomicin in the Treatment of Clostridium Difficile Infection (CDI)

Evaluation of Fidaxomicin in the Treatment of Clostridium Difficile Infection (CDI)

This is a single center collection of discarded biological samples and electronic medical review (EMR) data on patients who are hospitalized with clostridium difficile infections and treated with Fidaxomicin

This single site study will be a clinical research data base of patients hospitalized and diagnosed with Clostridium difficile infection (CDI), treated with Fidaxomicin and willing to allow us to collect discard biological samples for testing and analysis in the investigators lab. An additional blood sample will be obtained if a clinically indicated bronchoscopy is performed as to measure the amount of medication in the BAL. We will also complete a medical record review will also occur.

Inclusion Criteria:

1. ≥18 years of age
2. Currently an inpatient at UPMC Presbyterian
3. Diagnosed with an CDI
4. Being treated with Fidaxomicin

Exclusion Criteria:

not meeting entry criteria